Graphical Abstract Highlights d Single-cell RNA-seq reveals distinct CD45 + cells associated with clinical outcome d The balance between two CD8 + T cell states is linked with tumor regression d TCF7 + CD8 + T cell frequency in tumor tissue predicts response and better survival d Dual blockade of CD39 with different checkpoint proteins enhances immunity
In Brief
Single-cell analysis of immune cells from melanoma patients treated with immune checkpoint therapy uncovers a TCF7 + memory-like state in the cytotoxic T cell population and demonstrates its association with a positive outcome.
SUMMARY
Treatment of cancer has been revolutionized by immune checkpoint blockade therapies. Despite the high rate of response in advanced melanoma, the majority of patients succumb to disease. To identify factors associated with success or failure of checkpoint therapy, we profiled transcriptomes of 16,291 individual immune cells from 48 tumor samples of melanoma patients treated with checkpoint inhibitors. Two distinct states of CD8 + T cells were defined by clustering and associated with patient tumor regression or progression. A single transcription factor, TCF7, was visualized within CD8 + T cells in fixed tumor samples and predicted positive clinical outcome in an independent cohort of checkpoint-treated patients. We delineated the epigenetic landscape and clonality of these T cell states and demonstrated enhanced antitumor immunity by targeting novel combinations of factors in exhausted cells. Our study of immune cell transcriptomes from tumors demonstrates a strategy for identifying predictors, mechanisms, and targets for enhancing checkpoint immunotherapy.
INTRODUCTION
Antibodies that block immune checkpoint proteins, including CTLA4, PD-1, and PD-L1 (Callahan et al., 2016) , are FDA approved for treating a wide variety of cancers, including melanoma and non-small-cell lung carcinoma. In melanoma, despite the high response rate (Larkin et al., 2015; Robert et al., 2015) , most patients are refractory to therapy or acquire resistance. Identification of components that drive or prevent effective responses to checkpoint therapy thus remains an urgent need for understanding and expanding the use of immunotherapy in patients.
Checkpoint therapies were developed to overcome the dysfunction or exhaustion of T cells (Speiser et al., 2016; Wherry et al., 2007) resulting from chronic antigen exposure and suppression by the tumor or cells in its microenvironment. However, it remains unclear why some patients respond to checkpoint therapy while others do not. One factor associated with outcome is the number of infiltrating CD8 + T cells detected before (Tumeh et al., 2014) or during early treatment . In addition, several studies have found a correlation with signatures of T cell states, including signatures of IFNg responses as well as those of T cell activation, exhaustion, and cytotoxicity (Ayers et al., 2017; Prat et al., 2017; Riaz et al., 2017) ; abundance of partially exhausted CD8 + T cells in responding tumors (Daud et al., 2016) ; and magnitude of T cell reinvigoration in relation to pretreatment tumor burden in blood (Huang et al., 2017) . Additional studies have implicated non-T cell factors, including PD-L1 protein expression (Larkin et al., 2015) ; load of tumor neoantigens (Rizvi et al., 2015; Snyder et al., 2014) ; defects in antigen presentation and IFNg pathways (Gao et al., 2016; McGranahan et al., 2017; Sade-Feldman et al., 2017; Zaretsky et al., 2016) ; and signatures of mesenchymal transition, wound healing, and angiogenesis (Hugo et al., 2016) . One limitation of many of these studies is that the exact states of individual cells were not determined, either because bulk tumor biopsies or a limited set of predefined markers were used, thus limiting our ability to interpret the cellular basis for response to checkpoint inhibitors. To address these limitations, we applied high-dimensional single-cell RNA sequencing (scRNAseq) to determine the states of immune cells from dissociated tumor biopsies of patients treated with checkpoint therapy. We focused our analysis on two unique states of CD8 + T cells that predicted the success or failure of checkpoint immunotherapy and analyzed the immunological programs and functional properties of these T cells in the context of tumor immunity.
RESULTS

Single-Cell Profiling of Immune Cells in Tumors of Patients Treated with Checkpoint Inhibitors
To analyze immune cells associated with efficacy of checkpoint therapies, we performed scRNA-seq on immune cells isolated from 48 tumor biopsies taken from 32 metastatic melanoma patients treated with checkpoint therapy (with 35 anti-PD-1, 11 anti-CTLA4+PD-1, and 2 anti-CTLA4 samples), including 11 patients with longitudinal biopsies and 20 patients with 1 biopsy (or 2 for one patient), taken either at baseline or during treatment ( Figure 1A ; Table S1 ). We used the following patient response categories defined by RECIST criteria: complete response (CR) and partial response (PR) for responders or stable disease (SD) and progressive disease (PD) for non-responders (Eisenhauer et al., 2009) . However, to relate molecular and cellular variables with responses of individual lesions to therapy, we classified each of the 48 tumor samples based on radiologic assessments into progression/non-responder (NR; n = 31, including SD/PD samples) or regression/responder (R; n = 17, including CR/PR samples) (Table S1 ). Of 19,392 sorted and sequenced CD45 + cells (using an optimized full-length Smart-seq2 protocol [Villani et al., 2017] with a median of $1.4 million paired-end reads per cell), 16,291 cells passed quality control, with a median of 2,588 genes detected per cell (Method Details). Whole-exome sequencing (WES) available for 20 patient tumor and normal pairs, identified four tumors with somatic mutations in B2M, JAK1, STAT1, and IFNGR1 (Table S1) , recently associated with primary or acquired resistance to checkpoint therapy in melanoma (Gao et al., 2016; Sade-Feldman et al., 2017; Zaretsky et al., 2016) .
The Immune Cell Composition of Melanoma Tumors and Their Association with Response to Checkpoint Therapy To define the immune landscape and its association with outcome in an unbiased manner, unsupervised clustering of 16,291 CD45 + cells was used to identify a robust 11-cluster solution ( Figure S8 ; Method Details), with two B cell clusters (G1, B cells; G2, plasma cells), two myeloid clusters (G3, monocytes and/or macrophages; G4, dendritic cells), and seven clusters enriched for T/NK/NKT cells (G5-11) (Figures 1B and 1C;  Table S1 ). While each patient showed changes in cluster frequencies between baseline and post-treatment samples (Table S1 ), there were no consistent changes when aggregating all samples (Table S1 ). When we consider regression or progression of each lesion, two clusters (G1, p = 0.003; G10, T cells, p = 0.03; two-sided Wilcoxon rank-sum test) were more frequent in responder lesions, while four clusters (G3, p = 0.003; G4, p = 0.015; G6, T cells, p = 0.005; G11, T/NK cells, p = 1.3 3 10 À5 ) were more frequent in non-responder lesions ( Figure 1D ; Table S1 ). G6 and G11 were both enriched for genes linked to T cell exhaustion (LAG3, PDCD1, HAVCR2, TI-GIT, CD38, ENTPD1) and G11 for cell cycle genes (CDK1, CCNB1, MKI67, CDK4, RB1, TP53) (Table S1 ). Consistent with the unsupervised analysis, known signatures of exhausted and activated T cells (Fuertes Marraco et al., 2015; Wherry et al., 2007) (Table S1 ) were enriched in non-responder (p = 0.002) and responder lesions (p = 2 3 10 À4 ), respectively ( Figure 1E ), with no significant change between baseline and post-therapy samples ( Figure S1 ; Table S1 ); B cells, CD8 + , and CD4 + memory T cells were enriched in responder (p = 0.004, 0.001, and 0.03, respectively; Figures 1F and 1G) and myeloid cells in non-responder lesions (p = 0.002; Figure 1F) . We also identified individual markers based on the fraction of cells expressing a marker in responder versus nonresponder lesions ( Figure 1H ; Table S1 ), including PLAC8, LTB, LY9, SELL, TCF7, IGKC, and CCR7 in responder and CCL3, CD38, HAVCR2, ENTPD1, and WARS in non-responder lesions. Our analysis thus identified specific cell types, states, and markers associated with regression or progression of individual tumors in response to checkpoint therapy. (C) Heatmap displaying scaled expression values of discriminative gene sets per cluster as defined in (B) . A list of representative genes is shown per cluster. (D) Boxplots showing the % of cells (of all CD45 + cells) per sample for clusters that had a significant difference in frequency between responder and nonresponder lesions. Each point represents a single lesion. (E-G) Boxplots comparing % of cells between responder and non-responder lesions with exhausted or activated signatures for CD45 + CD3 + cells (E), B cells and myeloid cells (F) , and memory CD8 + and CD4 + T cells (G) based on known markers (Table S1 ). Each symbol represents a single lesion. (H) Heatmap displaying scaled expression values of genes that best discriminate between responder and non-responder lesions for all CD45 + cells. Best marker genes are sorted by fold change (Table S1 ). Colored circles on left show the cluster in which the gene is enriched. Data are represented as mean ± SEM.
Unbiased Definition of CD8 + T Cell States and Their Association with Therapy Response
Based on the high frequency of CD8 + T cells and the association of T cell states with clinical responses, as well as the established role of CD8 + T cells in recognition of tumor antigens and control of tumors (Pardoll, 2012; Tumeh et al., 2014) , we focused our analysis on CD8 + T cells. Clustering all CD8 + T cells (n = 6,350) revealed two major cell states: CD8_G with increased expression of genes linked to memory, activation, and cell survival (e.g., IL7R, TCF7, REL, FOXP1, FOSL2, and STAT4) (Hurton et al., 2016) and reduced expression of co-inhibitory molecules; and CD8_B enriched for genes linked to cell exhaustion (e.g., CD38, HAVCR2, ENTPD1, PDCD1, BATF, LAG3, CTLA4, and PTPN6) (Figures 2A and 2B ; Table S2 ). CD8_G cells mapped primarily to G10, G5, and G8 clusters, while CD8_B cells to G11 and G9 ( Figure S2A ), and both clusters were found in a published scRNA-seq dataset of melanoma (Tirosh et al., 2016) (Figures S2H and S2I; Table S2 ). CD8_G cells were enriched in responding lesions (two-sided Wilcoxon p = 1.4 3 10 À6 ), while CD8_B cells were enriched in non-responding lesions (p = 0.005; Figure 2C ), with both clusters coexisting in all lesions. Most responders had a cell-number ratio of CD8_G/CD8_B > 1, and most non-responders a ratio <1 for both baseline and post-treatment samples ( Figure 2D , S2B, and S2C). For the nine non-responding lesions with a ratio >1, we hypothesized that these patients had productive immunity that selected for tumors with de novo resistance to checkpoint therapy. Based on WES, immunohistochemistry, and flow cytometry, six out of nine samples (no DNA or slides were available for the other three) showed complete loss of B2M or HLA-A,B,C, as previously reported (Sade-Feldman et al., 2017; Zaretsky et al., 2016) (Figures  S2D and S2E; Table S1 ). We classified lesions as responders or non-responders based on CD8_G/CD8 ratios with high predictive power (area under the curve [AUC] of receiver operating characteristic [ROC] = 0.87; one-sided Wilcoxon p = 1.1 3 10 À5 ). However, when excluding six samples known to lack B2M or HLA-A,B,C, the predictive power was boosted (AUC of ROC = 0.95; p = 3.8 3 10 À7 ; Figure S2F ). We also identified individual CD8 + T cell markers (based on fraction of cells expressing a marker) (Figures 2E and S2G; Table S2 ) associated with response (TCF7, IL7R) and lack of response (e.g., CCL3, CD38, CLTA, ENTPD1, EPSTI1, FABP5, HAVCR2, NDUFB3, PDCD1, PRDX3, SIRPG, SNAP47, SNRPD1, UBE2F, and WARS) . These analyses revealed exhausted-like and memorylike CD8 + T cell states and markers that associate with lesionlevel response to checkpoint therapy.
Elevated Frequencies of TCF7 + CD8 + T Cells in Fixed
Tumor Specimens Predict Positive Outcome in an Independent Anti-PD-1-Treated Cohort To test our findings in an independent melanoma cohort (33 patients treated with anti-PD-1, n = 43 samples) with a different method, we stained fixed sections for CD8 and TCF7, a top marker associated with responding lesions and expressed frequently in CD8_G cells (Table S3 ). TCF7 is part of the Wnt/ b-catenin signaling pathway and is crucial for differentiation, Cell 175, 998-1013, November 1, 2018 1001 (legend continued on next page) self-renewal, and persistence of memory CD8 + T cells (Zhou et al., 2010) and reinvigoration and effective immunity of CD8 + T cells against chronic lymphocytic choriomeningitis mouse virus (LCMV) infection upon anti-PD-1 treatment (Im et al., 2016; Utzschneider et al., 2016) . Based on automated image analysis with CellProfiler (Carpenter et al., 2006) ( Figures 3A and 3B ; File S1), we found more TCF7 + CD8 + cells in responding (twosided Wilcoxon p = 3.9 3 10 À6 ) and more TCF7 À CD8 + cells in non-responding (p = 1.1 3 10 À8 ; Figures 3C and 3D ) samples. Most responders had a ratio of TCF7 + CD8 + to TCF7 À CD8 + cell number >1 while non-responders had a ratio <1 in all (n = 43; one-sided Wilcoxon p = 2.4 3 10 À6 ), baseline (n = 24; p = 0.001), or post-treatment (n = 19; p = 1.7 3 10 À4 ; Figure 3E ) samples. In contrast, the frequency of tumor-associated CD8 + T cells was not different between responder and non-responder patients ( Figure 3F ), as we found in the single-cell analysis ( Table  S1 ). The power to classify responses based on immunofluorescence analysis was high for all (AUC of ROC = 0.91), baseline (AUC of ROC = 0.88), or post-treatment samples (AUC of ROC = 0.98; Figure 3G ). Finally, patients with a ratio >1 survived longer than those with a ratio <1 (Kaplan-Meier [KM] log rank p = 0.03, Figure 3H ). Thus, staining of the TCF7 protein in CD8 + T cells may serve as a useful and practical marker of clinical outcome in patients treated with anti-PD-1 therapy.
Fine Clustering of CD8 + T Cells
While the two CD8 + T cell clusters were sufficient to separate responders from non-responders, unsupervised clustering further defined six sub-clusters, with three that are mostly contained within CD8_G and three within CD8_B (Figures 4A-4C; Method Details). CD8_1 cells expressed markers of exhaustion and cell cycle (Table S4 ; similar to G11; Table S1 ), similar to terminally exhausted CD39 + (ENTPD1) CD8 + T cells from chronic infection with hepatitis C virus . CD8_2 cells expressed many of the same exhaustion markers along with heat shock proteins (HSPB1, HSPA1A, and HSPA4) and additional inhibitory receptors (ENTPD1 and KIR2DL4). CD8_3 cells expressed the known exhaustion markers (HAVCR2, CD38, PDCD1, and PTPN6) but lacked heat shock and cell-cycle genes. CD8_4 (CCR7, IL7R, TCF7, TNF, and S100A10) and CD8_6 (SELL, TCF7, LTB, IL7R, FLT3LG, and IL16) cells were consistent with a memory-and/or effector-like phenotype, while CD8_5 cells had the phenotypes of memory and early activated cells (IL6ST, CXCL13, IL7R, and CTLA4) with higher HAVCR2 and PDCD1 compared to CD8_4,6 but lower than CD8_1,2,3 (Figure S3A) . Interestingly, GZMA, GZMB, and PRF1 had much higher expression in CD8_1,2,3 (Table S4) , resembling programs previously reported in melanoma (Tirosh et al., 2016) , in a mouse model of chronic LCMV infection (Wherry et al., 2007) , and in resident memory T cells (Mami-Chouaib et al., 2018) . CD8_1 and CD8_3 were enriched in non-responder (one-sided Wilcoxon p = 6.7 3 10 À5 and p = 0.001, respectively), while CD8_4 and CD8_5 were enriched in responder lesions when excluding samples deficient for B2M or HLA-A,B,C (p = 0.01 and p = 0.02, respectively; Figure 4D ). CD8_5 was found mostly in post-therapy samples (80%; Figures S3B and S3C ) and appeared to have fewer TCF7-expressing cells relative to CD8_4 and CD8_6 ( Figure S3A ). However, it split into two sub-clusters ( Figure 4E ): CD8_5.1 (TCF7 + GZMB À ) and CD8_5.2 (TCF7 À GZMB + ) cells, both enriched in responder lesions (onesided Wilcoxon p = 0.01 and p = 0.04, respectively). These findings are consistent with a recent study showing that loss of TCF7 expression is associated with acquisition of effector phenotype in response to anti-PD-1 treatment in a mouse model of LCMV infection (Im et al., 2016) . Since T cells transition to new states in cancer or chronic infections (Im et al., 2016; Speiser et al., 2016) , we used trajectory analysis (Qiu et al., 2017) to identify a main trajectory branch and two side branches ( Figure 4F ), reflecting a possible path for differentiation (CD8_4, CD8_6, CD8_5 followed by CD8_3, CD8_2, and CD8_1, with some overlap of clusters and with no information on the directionality) (Figures 4F, S3D, and S3E) . The finding of transitional cells and the proximity between clusters suggests states that may arise or give rise to others. Our analysis of finer T cell states is consistent with our findings of the two CD8 + T cell clusters but provides better resolution of cell states and suggests testable paths for differentiation.
TIM3 and ENTPD1 Mark the Exhausted-like State of CD8 + T Cells To isolate cells with the different CD8 + T cell states using flow sorting, we used the cell surface markers, CD39 (ENTPD1) and TIM3 (HAVCR2), which both had low expression in clusters associated with response and high expression in those associated with no response (Figures S3A and S4A; Tables S2 and S4) . We used scRNA-seq to profile freshly sorted CD39 + TIM3 + (DP, double positive) and CD39 À TIM3 À (DN, double negative) CD8 + T cells from four melanoma patients ( Figure S4B ; Table S5 ) and found that the profiles recapitulated the original unsorted clusters ( Figures 5A and 5B )-DN with CD8_4 and 6, and DP mostly with CD8_2 cells. Since CD39 is an ectonucleotidase in the adenosine pathway that modulates immunity (Young et al., 2014) , a marker for terminally exhausted CD8 + T cells in patients with chronic hepatitis C virus (HCV) and HIV infections , and a marker of exhaustion in tumor-infiltrating CD8 + T cells in melanoma and breast cancer (Canale et al., (legend continued on next page) 2018), we analyzed the properties of CD8 + CD39 + from 12 melanoma patients treated with checkpoint blockade therapy (Table  S5 ). We found that while CD8 + CD39 + and CD8 + CD39 À T cells had equal expression of PD-1, CD39 turned out to be a key marker that separates all TIM3 + from TIM3 À cells ( Figure S4C ), the latter being reported as a marker of T cell dysfunction in cancer and chronic infections (Anderson et al., 2016) . We prepared single-cell suspensions from the 12 patients and assessed their ability to produce cytokines in response to T cell receptor (TCR) (anti-CD3/CD28) stimulation. While CD39 À and CD39 + cells contained equivalent percentages of IL-2-producing cells, CD39 + cells had a significant reduction in the number of TNF⍺-(unpaired-Student's t test p = 0.0016) and IFNg-producing cells (p = 5 3 10 À4 ; Figure 5C ). To address which of the two cell states (DN or DP) is important for tumor eradication upon anti-PD-1 therapy, we used a CT26 GFP+ mouse tumor cell-line that exhibits modest regression when treated with anti-PD-1 in an ex-vivo three dimensional (3D) microfluidic culture system for growing murine organotypic tumor spheroids (MDOTS) (Jenkins et al., 2018) . We found anti-PD-1-mediated killing using this system was dependent on both CD8 + T cells and IFNg ( Figure 5D ). Next, we isolated CD8 + CD39 À TIM3 À (DN) and CD8 + CD39 + TIM3 + (DP) cells from CT26 GFP+ tumors and immediately incubated each population or a mixed one (DN/DP, 1:1 ratio) in the device with the MDOTS for 5 days with anti-PD-1 (or anti-IgG control antibodies), followed by live/dead staining and fluorescence microscopy to evaluate the viability of the CT26 GFP+ MDOTS ( Figure S4D ). Addition of DN cells (which were also TCF7 + ) induced the most cell death, with $50% of GFP + tumor cells eradicated after 5 days with anti-PD-1 antibodies, while DP cells reduced killing to control (IgG) levels ( Figure 5D ). We conclude that expression of CD39 and TIM3 discriminated exhausted from memory and/or effector cells, with DN cells supporting antitumor activity of checkpoint blockade ex vivo.
Dual Inhibition of TIM3 and CD39 Reduces Tumor Growth and Improves Survival
Because cells expressing CD39 and TIM3 were associated with non-responding lesions, and their expression was highly correlated with each other (relative to all pairwise correlations between top CD8_B markers; Table S5 ), we examined the combined effect of CD39 and TIM3 blockade. Mice transplanted with B16-F10 melanoma were treated with a small molecule, POM-1, that inhibits CD39 activity (Sun et al., 2010) and/or anti-TIM3 blocking antibodies ( Figure 5E ). While either monotherapy transiently reduced tumor growth through day 14, the combination strongly reduced tumor size and increased survival at day 40 to 20% versus 0% for monotherapy ( Figures 5F, 5G , S4E, and S4F). Combining POM-1 treatment with anti-PD-1 or anti-PD-1/CTLA4 also reduced tumor growth and increased survival, with POM1/PD-1/CTLA4 therapy having a strong synergistic boost of survival at day 40 to 60% (Figures 5H-5K and S4G-S4J). The effects of POM-1 were dependent on CD8 + but not CD4 + T cells ( Figures S5A-S5E ) and led to higher frequencies of IFNg-but not GZMB/PRF1-producing CD8 + T cells (unpaired-Student's t test p = 0.04) and higher T cell proliferation in response to TCR stimulation ( Figures S5F-S5I ). While surface CD39 levels were not altered by POM-1 in CD8 + and B16-F10 GFP+ cells ( Figure S5J ), ATP levels increased in whole tumor (p = 0.02) or B16-F10 GFP+ cells (p = 0.02; Figure S5K ), suggesting that CD39 ATPase is active in B16-F10 tumors. These results are consistent with prior studies in which inhibition of CD39 enzymatic activity enhances proliferation of T cells (Bastid et al., 2015) . Altogether, we observed enhanced tumor control when targeting CD39 in combination with TIM3 or other checkpoints, providing new and effective therapeutic combinations.
Chromatin States of Exhausted-like and Memory-like CD8 + T Cells
To better understand the transcriptional regulation that explains the signatures observed in the exhausted-like and memory-like CD8 + T cells, DP and DN cells were isolated from five metastatic melanoma patients (Table S5) , and open chromatin was quantified by assay for transposase-accessible chromatin using sequencing (ATAC-seq) and transcript levels by scRNA-seq (Figure 6A) . Of the differentially expressed transcription factors (TFs) by scRNA-seq, DN cells expressed higher levels of TCF7, STAT4, FOXP1, and FOSB transcripts, as observed for stem cell memory CD8 + T cells (Hurton et al., 2016) , and DP cells expressed higher BATF, PRDM1, TOX, HMGB2, and IRF2, as described for exhausted CD8 + T cells (Waugh et al., 2016; Wherry et al., 2007) ( Figure 6B ). These TFs were also detected in single cells sorted computationally based on expression of CD39 and TIM3 mRNAs as well as in the original CD8_G and CD8_B clusters ( Figures S6A and S6B ). ATAC-seq identified differentially accessible regions in genes related to exhaustion and memory (Figures 6C, 6D, and S6C), with a smaller number in DN cells (424; Benjamini-Hochberg false discovery rate [FDR] < 0.01; Table S5 ) when compared to DP cells (858; FDR < 0.01; Table S5 ), consistent with a previous study showing increased open regions as cells differentiate in response to chronic LCMV infection (Sen et al., 2016) . Next, we searched for TF motifs enriched in open chromatin peaks and found BATF (and other TFs) motifs enriched in DP peaks and TCF7 and FOXP1 motifs in DN peaks ( Figure 6E ). EOMES was highly expressed in DP cells consistent with previous studies (Paley et al., 2012; Wherry et al., 2007) ; however, differential peak motif (C) Hierarchical tree structure for six clusters, with each split showing genes upregulated in the corresponding cluster relative to the rest of the cells found in the last common ancestor. (D) % of cells in CD8_1 to CD8_6 clusters (out of all CD8 + T cells). (E) tSNE plot of CD8 + T cells with coloring of CD8_5 according to TCF7 expression (upper) and TCF7 and GZMB expression (lower). Figure 4A ) in which the gene is enriched. (C) Representative flow cytometry plots for intracellular staining of IL-2, IFNg, and TNF⍺ in CD39 À and CD39 + cells, with quantification below for 12 patients. Data were combined from two replicate experiments. (D) Quantification of live/dead cells based on staining of CT26 GFP+ MDOTS on day 5 of ex vivo culture. One of two independent experiments is shown, with n = 3 replicates per group per experiment. 2-way ANOVA, Tukey's multiple comparisons test. (E) A schematic summary of the therapy regimen used in the transplantable B16-F10 mouse model. (legend continued on next page) enrichment was found in DN cells, suggesting that TF activity and expression are not coupled. Since BATF and TCF7 had the highest peak motif enrichment and the highest expression in DP and DN, respectively ( Figures 6E and S6D) , we compared whether differentially expressed genes near significant (FDR < 0.01) open chromatin regions (OCR) in DP or DN cells (as defined by GREAT [McLean et al., 2010] ) contain enhancers with BATF or TCF7 motifs. We identified 95 genes in DP (16%, including CXCL13, ENTPD1, CD38, CTLA4, and HAVCR2) and 6 genes in DN cells (20%, including IL7R, PLAC8, and SELL), out of the total differentially expressed genes (584 for DP and 30 for DN), that meet these criteria ( Figure 6F ), suggesting that both BATF and TCF7 control the expression of key genes unique to each cell state. Furthermore, BATF was associated with nonresponder lesions when looking at all cells (Fisher's exact test p = 7.2 3 10 À49 ; Table S1) or CD8 + cells (p = 8.1 3 10 À19 ; Table  S2 ), and TCF7 with responder lesions (all CD45 + , p = 8.03 3 10 À50 ; CD8 + , p = 3.02 3 10 À20 ). Finally, we compared open chromatin in DP and DN cells to those of recently reported dysfunctional PD-1 high CD8 + cells and central memory cells (CD45RA À C-D45RO + CD62L lo ) . We found an overlap of DP with PD-1 high CD8 + and DN with central memory cells but with some unique peaks in each (Benjamini-Hochberg FDR < 0.01; Figure S6E ; Table S5 ), showing that they share some of their programs. Our analysis reveals key regulatory elements and TFs that regulate the exhaustion-like and memory-like programs in CD8 + T cells found in human melanoma.
TCR Analysis Identifies Patterns of Expansion Associated with Cell States and Clinical Outcome
We reconstructed TCR sequences for all identified CD8 + T cells and defined four patterns of TCR clonality based on shared CDR3 sequences in both ⍺ and b chains ( Figure 7A ; Method Details): persistent TCRs detected in pre-and post-therapy samples from the same patient, enriched TCRs detected in more than one T cell in a single sample, singlet TCRs found in only one T cell at one time point, and common TCRs shared across two or more patients. Since the overall number of persistent TCRs was very low, especially in responders, we could not make many conclusions about their relationships to clinical response; still, we detected a significant enrichment for persistent TCRs in non-responders in clusters CD8_3 (two-sided Wilcoxon p = 0.01) and CD8_6 (p = 0.006) ( Figure 7B ), and when aggregating exhaustion clusters (CD8_1,2,3, p = 0.02) but not the memory and/or effector ones ( Figure 7C ). Interestingly, very few persistent TCRs were detected in the CD8_5 cluster (which was present predominantly in post-therapy samples) when looking at all patient CD8 + cells ( Figure 7D ), suggesting that these T cell clones did not exist prior to therapy. Enriched TCRs were more common in exhausted clusters and singlet TCRs in effector and/or memory clusters ( Figures 7G and 7J ), but both were enriched in non-responders for CD8_1,2,3 and in responders for CD8_4,5,6 ( Figures 7F and 7I ). We hypothesize that enriched TCRs are likely to have been exposed to persistent tumor antigen stimulation, explaining their higher proportions in the exhausted than in the effector and/or memory clusters, while singlet TCRs are not as expanded because they are more recently generated against tumor antigens (or are bystanders) and have fewer exhaustion markers. Although common TCRs were predominantly present in clusters CD8_2 and 3, no significant association was found with clinical outcome ( Figures  7K-7M ). Collectively, this analysis allowed us to connect the transcriptional phenotype of cells and therapeutic outcomes with TCR clonality and could aid in investigating T cell dynamics and cell state plasticity. Indeed, when looking at the transitions of T cell states (CD8_1,2,3,4,5,6) within a specific clone (based on identical TCR sequence) across longitudinal samples in the same patient (Table S6) , we discovered bilateral transitions between exhausted and memory and/or effector states.
DISCUSSION
Although immune checkpoint blockade leads to durable responses in patients with metastatic melanoma, refractory disease and progression after initial response remain major causes of mortality (Larkin et al., 2015; Robert et al., 2015) . By profiling single immune cells in baseline and on-or post-therapy samples in melanoma patients treated with checkpoint therapy, we identified and characterized several CD8 + T cell states associated with lesion growth and studied their properties using a series of molecular and functional experiments.
A central finding from our study is that the presence of TCF7 protein in CD8 + T cells can predict clinical response to checkpoint therapy, suggesting that the state of T cells, in addition to the number of T cells and their spatial distribution (Galon et al., 2006; Mahmoud et al., 2011; Sharma et al., 2007) , found in a patient's tumor is critical for induction of effective tumor immunity. Consistent with our findings, TCF7 (TCF1 in mice) is required for reinvigorating CD8 + T cells in response to PD-1 blockade to resolve chronic LCMV infection (Im et al., 2016; Utzschneider et al., 2016) , and for the expansion of CXCR5 + TIM3 À CD8 + T cells (but not TIM3 + cells) for control of virus in mice (Im et al., 2016) , although we did not observe CXCR5 expression in TCF7 + cells in human melanoma. Finally, our results also agree with recent studies showing a reduction in open chromatin regions at TCF7 sites in non-programmable, dysfunctional PD-1 high T cells and with the importance of TCF7 role for WNT signaling in stem cell-like memory cells (Gattinoni et al., 2009) .
In contrast to TCF7 + CD8 + T cells, we found cells expressing exhausted or dysfunctional signatures associated with lack of response to checkpoint therapy. Our finding of CD39 (an enzyme in the adenosine pathway) as a marker of exhausted CD8 + T cells is consistent with recent observations in melanoma (Canale et al., 2018) and HCV-and HIV-infected patients (Gupta et al., (I) Survival of B16-F10 tumor-bearing mice treated with CD39i + anti-PD-1. 
Graph depicting enrichment of TF motifs based on open chromatin specific to CD39 À TIM3 À (blue) versus CD39 + TIM3 + (orange) cells (x axis) and differential expression of TFs (y axis). (F) Left: Enhancer binding sites for BATF and TCF7 near the listed genes. Significant genes, red; non-significant, white. The same genes are also differentially expressed between CD39 + TIM3 + cells and CD39 À TIM3 À cells. Right: The number of genes that are differentially expressed with a corresponding differential peak containing BATF or TCF7 is shown. 2015). The ability of CD39 inhibitors together with TIM3, PD-1, or PD-1/CTLA4 blockade to reduce tumor growth and increase survival of mice with B16-F10 tumors is consistent with studies using checkpoint blockade with inhibitors of CD73 (a downstream component of the adenosine pathway) (Allard et al., 2013) and
suggests new therapeutic combinations for treating melanoma and other cancers. Some studies used bulk tumor expression data to identify several signatures (IFNg, exhaustion, cytotoxicity, antigen presentation, and others) that associate with outcome (Ayers Prat et al., 2017; Riaz et al., 2017) . However, since many distinct signatures are upregulated at the same time in responders, one interpretation of these findings is that the bulk transcriptome change (which mixes many immune and non-immune cells together) likely reflects an overall increase in the T cell infiltrate and does not discriminate specific T cell states. Consistent with this notion, we find that signatures of CD8_G and CD8_B, as well as known markers of T cell states (exhausted, effector, memory), are equally correlated with CD3 transcript number in samples from these cohorts ( Figure S7 ).
We also show evidence that T cells can transition between states based on identical TCRs in T cells from exhausted-like and memory-like states, but we do not know the order or the exact transitions between states. Surprisingly, we found that CD 8_5 T cells, which were predominantly found in post-therapy tumor samples, hardly share TCRs with the baseline sample, suggesting that members of the CD8_5 cluster are generated outside of the tumor and subsequently migrate to the tumor, consistent with observations from a recent study (Spitzer et al., 2017) demonstrating that lymphoid-organ-derived T cells are required for anti-PD-1 potency.
Future studies will need to purify cells in each of the different T cell states based on surface protein markers (which may not always correlate with transcripts), validate their purity by scRNA-seq, and study their properties (as we did for some of the states here). Indeed, we identified a T cell state associated with response and showed that CD39 À TIM3 À CD8 + T cells (which are TCF7 + ) contribute to the antitumor activity of anti-PD-1 therapy in culture, but we have not yet determined which cells kill the tumors, the role of PD-1 in this process, or the factors that induce or attract TCF7 + T cells.
Our finding that specific memory-like signatures are associated with response-together with recent studies showing that chimeric antigen receptor (CAR) T cell activity is enhanced by generating more memory-like cells through IL-7 or IL-15 pathways, leading to better outcome in preclinical models (Hurton et al., 2016; Shum et al., 2017) -suggests that methods to increase the ratio of CD8_G to CD8_B would enhance immunotherapies. Indeed, we were able to increase ex vivo tumor killing by removal of CD39 + TIM3 + CD8 + T cells (from tumor infiltrates) prior to treatment with anti-PD-1.
Building on the results and datasets presented here, one can envision designing trials that select patients for anti-PD-1 therapy based on T cell states and markers and then testing whether this strategy increases the rate of durable responses. In addition, it may be possible to use the change in the ratio of T cell states as an assay to prioritize therapeutic approaches prior to anti-PD-1 therapy. Future studies will also need to test whether our predictive markers of response are relevant to other types of malignancies and therapies.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
Mice
Female C57BL/6 or BALB/cJ mice, age of 8-9 weeks were purchased from Jackson Laboratory and were housed at Massachusetts General Hospital under SPF conditions. All experiments followed protocols approved by the Massachusetts General Hospital Institutional Animal Care and use Committee (IACUC).
In vivo tumor transplant experiments B16-F10 and CT26 cells were generously provided by Mikael Pittet and Umar Mahamood respectively. B16-F10 or B16-F10 GFP+ cells (0.5x10 6 ) were intradermally injected into the right flank using a 30 g needle and tumors were measured every 4 days in two dimensions using a digital caliper. Tumor volume (mm 3 ) was calculated using the following formula V = (L * W 2 )/2 (V = volume, L = tumor length, tumor width). For MDOTS experiments, CT26 GFP+ cells (2x10 6 ) were subcutaneously injected into the right flank using a 27 g needle and tumors were harvested 14 days post transplantation. All blocking treatments started on day 4 post transplantation after 100% of tumors were visible. Invivo plus rat IgG2a isotype control (BioXCell; 2A3; BE0089) 100mg/dose was intraperitoneally (i.p.) injected to the control (untreated) group every 3 days. Invivo plus anti-mouse TIM3 (BioXCell; RMT3-23; BE0115) 100mg/dose, Invivo plus anti-mouse PD-1 (BioXCell; 29F.1A12; BE0273) 200mg/dose and Invivo plus anti-mouse CTLA4 (BioXCell; 9D9; BE0164) 100mg/dose were i.p. injected every 3 days. POM-1 (polyoxometalate-1) 5mg/kg/day (Santa Cruz Biotechnology; sc-203205), a CD39 inhibitor, was i.p. injected on a daily basis, starting on day 4 post transplantation.
METHOD DETAILS
Sample dissociation
Fresh isolated tumor samples were collected immediately after surgery and were dissociated within 1 hour using the human tumor dissociation kit (Miltenyi Biotec; 130-095-929) with the following modifications. Tissue was minced into small pieces using a scalpel and put into a 1.5ml eppendorf tube containing 100ml of enzyme H, 50ml of enzyme R, 12.5ml of enzyme A (all provided in the kit), and 837.5ml of RPMI, followed by a 20 minute incubation in a thermomixer (Eppendorf; F1.5) at 37 C, 600 rpm. After incubation, debris were removed by filtering through a 70mm cell strainer, followed by mincing of the remaining tissue left on the strainer with a plunger in order to increase cell yield. Dissociated cells were subsequently washed with cold 1X PBS containing 1.5% heat inactivated FCS, spun down at 1300 rpm, 4 C for 5 minutes, resuspended, and counted for yield and viability with trypan blue using a Countess automated cell counter (Invitrogen).
Flow cytometry and cell sorting
For both flow cytometry and cell sorting, Human or mouse TrueStain FcX (Biolegend, 422302 or 101320) was used for blocking Fc receptors before labeling cells. To discriminate live from dead cells, we used Zombie Violet Dye (Biolegend, 423114) or Zombie Green (Biolegend, 423111) for 15 min at 4 C, followed by surface labeling of cells for 30 min at 4 C, using standard protocols. The antibodies used for cell surface labeling were PE anti-human CD45 (Biolegend, 304008), APC anti-human CD3 (Biolegend, 300412), FITC antihuman HLA-A,B,C (Biolegend, 311404), APC/Cy7 anti-human CD235a (Biolegend, 349116), PE/Cy5 anti-human CD3 (Biolegend, 300309), BV421 anti-human PD-1 (Biolegend, 329919), PE/Cy7 anti-human TIM3 (Biolegend, 345013), APC/Cy7 anti-human CD39 (Biolegend, 328226), AF700 anti-human CD4 (Biolegend, 317425) and BV650 anti-human CD8 (biolegend, 301041). Antibodies used for cell surface of mouse cells were AF647 anti-mouse CD39 (Biolegend, 143808), BV605 or Pacific blue anti-mouse CD3 (Biolegend, 100351 or 100334), PE/Cy5 or FITC anti-mouse CD8a (Biolegend, 100710 or 100705), APC/Cy7 anti-mouse CD4 (Biolegend, 100414), BV650 or FITC anti-mouse CD45.2 (Biolegend, 109836 or 109806) and APC or Pacific Blue anti-mouse Thy1.2 (Biolegend, 140312 or 105324). The antibodies used for intracellular staining were FITC anti-human IFNg (Miltenyi Biotec, 130-097-936), PE antihuman IL2 (Miltenyi Biotec, 130-099-391), APC anti-human TNF⍺ (Miltenyi Biotec, , APC anti-mouse TNF⍺ (Biolegend, 506307), PE anti-mouse IL2 (Biolegend, 503807) , FITC anti-mouse IFNg (Biolegend, 505805) , PE anti-mouse Perforin-1 (Biolegend, 154305) and APC anti-mouse Granzyme-B (Biolegend, 372203) . Intracellular cellular labeling for granzyme-B and perforin-1 was performed following surface staining, fixation and permeabilization using the BD Transcription Factor Buffer Set (BD, 562574) according to the manufacturer's instructions. Sorting of single cells was performed on a BD Fusion instrument using the following antibody panel: Zombie dye, CD45, CD235a and HLA-A,B,C. CD45 + cells from dissociated samples were sorted into 96-well plates (Eppendorf, 951020401) containing 10ml of lysis buffer (TCL buffer, QIAGEN 1031576, supplemented with 1% b-mercaptoethanol), sealed, vortexed, spun down at 2500 rpm for 30 s, immediately placed on dry ice, and then stored at À80 C until processing with the Smart-Seq2 protocol. Sorting of human and mouse CD8 + CD39 + TIM + (DP) and CD8 + CD39 -TIM3 -(DN) was performed using the following antibody panel: Zombie dye, CD45, CD3, CD8, CD39, and TIM3. For flow cytometry, we used the Beckman Coulter CytoFLEX instrument and analyzed the data with FlowJo 10.4.2 software.
Single cell RNA sequencing procedure Libraries from single cell lysates were generated with the Smart-Seq2 protocol (Picelli et al., 2013) with some modifications in the reverse transcription step as recently described (Villani et al., 2017) . 96-well plates containing cell lysates were thawed on ice, spun down at 1500 rpm for 30 s, and mixed with Agencourt RNAClean XP SPRI beads (Beckman Coulter) for RNA purification. Purified RNA was resuspended in 4ml of Mix-1, denatured at 72 C for 3 min and placed immediately on ice for 1 min before 7ml of Mix-2 was added (Table S6 ). Reverse transcription was carried out at 50 C for 90 min, followed by 5 min incubation at 85 C. 14ml of Mix-3 was added in each well and the whole-transcriptome amplification step was performed at 98 C for 3 min, followed by 21 cycles at (98 C for 15 s, 67 C for 20 s and 72 C for 6 min), and final extension at 72 C for 5min. cDNA was then purified with Agencourt AMPureXP SPRI beads (Beckman Coulter) as described (Villani et al., 2017) , to remove all primer dimers residues. Quality control steps were performed on samples before library construction and included the following steps: (1) concentration measurements, using the Qubit dsDNA high sensitivity assay kit on the Synergy H1 Hybrid Microplate Reader (BioTek); (2) cDNA size distribution using the High-Sensitivity DNA Bioanalyzer Kit (Table S6 ). Libraries were generated using the Nextera XT Library Prep kit (Illumina) with custom indexing adapters (Villani et al., 2017) in a 384-well PCR plate, followed by a cleanup step to remove residual primer dimers. Combined libraries from 384 cells were then sequenced on a NextSeq 500 sequencer (Illumina), using paired-end 38-base reads.
Immunofluorescence assay and analysis
Multiplex staining was performed on 4mm formalin-fixed paraffin-embedded sections using the Opal multiplex IHC system (PerkinElmer; NEL800001KT) according to the manufacturer's instructions. Briefly, slides were baked for 1 hour at 65C followed by deparaffinization with xylene and a graded series of ethanol dilutions (100%, 95% and 70%), fixation with 10% neutral buffered formalin for 30 minutes, microwave antigen retrieval using the AR9 buffer (PerkinElmer; AR900250ML), and blocking. Primary antibodies used for staining were: CD8a (Biolegend; C8/144B; 372902; 1:100) detected with OPAL520 (1:100; Cy2); TCF7 (Cell Signaling; #2203; 1:100) detected with OPAL690 (1:100; Cy5.5). Counterstain was done using DAPI (1:1000) and subsequently mounted using Vectashield (Vectra; H-1000) fluorescence media. Slides were imaged using the Olympus IX83 confocal microscope by scanning 10 random fields on each sample at 40X magnification, and analyzed with CellProfiler 2.2.0 (Carpenter et al., 2006) to detect the total number of nuclei, CD8 + , TCF7 + , and CD8 + TCF7 + cells. Due to cellular heterogeneity between different slides/patients, in each sample the percentage of CD8 + TCF7or CD8 + TCF7 + was calculated out of the total nuclei detected. For the analysis, a new pipeline was made for detection of cells positive for CD8 and TCF7 (File S1).
Immunohistochemistry
Procedures were done on the automated Ventana Discovery Ultra staining system, using 4mm formalin-fixed paraffin-embedded sections. Sections were deparaffinized in xylene and graded alcohols, followed by antigen retrieval (EDTA), blocking with Discovery inhibitor (Ventana; 760-4840), incubation with primary antibodies for 16 minutes, washing and incubation with a secondary antibody conjugated with horseradish peroxidase (HRP). Sections were developed with discovery purple chromogen kit (Ventana; 760-229) and were then counterstained with hematoxylin. Primary antibodies used were: B2M (Abcam; ab27588; 1:1000); anti melanoma triple cocktail (Ventana; 790-4677; 1:100) containing antibodies against melanosome (HMB45), Mart-1/melan A (A103), tyrosinase (T311). The melanoma triple cocktail was used to separate tumor from normal cells enabling detection of B2M in the cancerous cell fraction.
Intracellular cytokine detection
For intracellular cytokine analysis of human CD8 + T cells, 5x10 5 cells from dissociated samples (n = 12) were cultured in the presence of soluble LEAF purified anti-CD3 (Biolegend, 317303, 2mg/ml), anti-CD28 (Biolegend, 302913, 1mg/ml) and GolgiPlug (BD, 555029) for 6 hours at 37 C. Intracellular cytokine labeling was performed following surface staining, fixation and permeabilization using the BD Cytofix/Cytoperm Plus kit (BD, 555028) according to the manufacturer's instructions.
Generation of B16-F10 GFP+ and CT26 GFP+ cells B16-F10 and CT26 cell lines were transduced with the lenti-GFP + virus FUGW (a gift from David Baltimore; Addgene, 14883) (Lois et al., 2002) , and GFP high -positive cells were sorted on day +5 to generate B16-F10 GFP+ and CT26 GFP+ cells. Before each experiment the percentage of GFP + cells was evaluated by flow-cytometry. For lentivirus production 293T cells were transfected with psPAX2 (a gift from Didier Trono; Addgene, 12260), FUGW and pMD2.G (a gift from Didier Trono; Addgene, 12259) at a 10:10:1 ratio using TransIT-LT1 reagent (MIRUS, MIR2300) according to the manufacturer's guidelines.
In vivo depletion of CD4 + and CD8 + T cells For depletion of CD4 + and CD8 + T cells 400mg/dose of Invivo mAb anti-mouse CD8a (BioXCell; 2.43; BE0061), 400mg/dose Invivo mAb anti-mouse CD4 (BioXCell; GK1.5; BE0003-1) or 400mg/dose rat IgG2b isotype control (BioXCell; LTF-2; BE0090), were i.p injected every 3 days, starting from day +7 post tumor transplantation until day +21. Depletion efficacy was evaluated on day +14 by flow cytometry analysis.
Ex vivo culture and live/dead imaging of Murine-derived Organotypic Tumor Spheroids CT26 GFP+ tumors from untreated BALB/cJ mice were harvested on day +14 following implantation. Murine-derived organotypic tumor spheroids (MDOTS) (S2 fraction; 40-100mm) isolation was performed as previously described (Jenkins et al., 2018) . Following isolation, MDOTS were resuspended in type I rat tail collagen and the spheroid-collagen mixture was injected into the center gel region of the 3D microfluidic culture device (10ml per AIM device). After incubation (30 min, 37 C in sterile humidity chambers), the collagen-MDOTS mixture was hydrated with media (10% FBS in RPMI) with the indicated therapeutic monoclonal antibodies: isotype control IgG2a (10mg/ml, BioXCell, BE0089), anti-PD-1 (10mg/ml, BioXCell, BE0146), anti-IFNg (10mg/ml, BioXCell, BE0054), and anti-CD8a (10mg/ml, BioXcell, BE0004-1). For TIM3/CD39 subpopulation studies, sorted CD8 + double-positive derived from the S3 (< 40mm) MDOTS fraction (DP; CD39 + TIM3 + ), double-negative (DN; CD39 -TIM3 -) and mixed (1:1 mixture of DP and DN cells) populations were pelleted and resuspended in MDOTS/collagen mixture at an estimated effector:target (E:T) ratio of $1:3-1:4 (based on estimated $10,000 cells per device). MDOTS were cultured in the DAX-1 3-D cell culture chip from AIM Biotech, as described (Jenkins et al., 2018) . On day +5 live/dead fluorescence staining was performed as previously described (Jenkins et al., 2018) with the following modifications. After incubation with Hoechst/PI (40 min, 37oC, 5% CO2) images were obtained. Image-capture and analysis were performed using a Nikon Eclipse 80i fluorescence microscope equipped with Z stack (Prior), motorized stage (ProScan) and ZYLA5.5 sCMOS camera (Andor) and NIS-Elements AR software package. Live/dead cell quantification was performed by measuring total cell area of each dye in GFP-positive CT26 cells.
CFSE labeling and ex vivo proliferation assay
Single cell suspensions (10x10 6 ) of digested B16-F10 GFP+ tumors isolated on day 14 post implantation (from POM-1 treated and untreated mice) were incubated with PBS (without Ca2 + and Mg2 + ) containing 5mM CFSE (Biolegend, 423801) for 10 min at 37 C. Heat inactivated fetal calf serum (FCS) was then added for 1 min, and cells were washed three times in RPMI + 10% FCS. CFSE-labeled cells (3x10 5 ) were seeded in triplicates in a 96-flat bottom plate with or without the presence of 1mg/ml anti-CD3/CD28 antibodies (Biolegend, 100314 and 102112) for 72h. The number of cell divisions of Thy1.2 + CD8 + cells was determined by flow-cytometry analysis.
Intra-tumoral ATP level measurements
Intra-ATP levels were measured immediately either in total single cell suspensions of digested B16-F10 GFP+ tumors or sorted B16-F10 GFP+ cells (1x10 5 ), isolated from POM-1 treated and untreated mice on day 14, using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, G7571) according to the manufacturer's guidelines. ATP levels were measured (in triplicates) using the Synergy H1M plate reader (BioTek), and its concentration was calculated using an ATP standard curve.
ATAC-seq tagmentation
Methods for tagmentation are as previously reported (Corces et al., 2016) . Briefly, 5,000-10,000 cells were cell sorted into RPMI containing 10% FBS, 1% Pen/Strep, 1% L-Glutamine, and 1% HEPES. The cells were then centrifuged at 500xg at 4 C for 10 minutes, the supernatant aspirated, and resuspended in tagmentation mixture (25 ml tagmentation buffer (Illumina, FC-121-1031), 2.5 ml TBE (Illumina, FC-121-1031), 0.5 ml 1% digitonin (Promega, G9441), and 22 ml H2O). The cells were then incubated at 37 C in a thermomixer, mixing at 300 RPM for 30 min. Following tagmentation, the sample was immediately purified via minElute PCR cleanup column (QIAGEN, 28006) , and eluted in 10 ml. The tagmented DNA was then PCR'ed using Nextera indexing primers with sequencing adapters for 5 cycles in a 50 ml reaction. 5 ml of the reaction was then used for qPCR to determine the remaining number of PCR cycles required (as determined by the cycle number of each sample when it reaches 1/3 the fluorescence threshold), followed by PCR of each individual sample according to this cycle number. The samples were purified using 1.5X Agencourt AMPure XP beads (A63880), followed by two 70% EtOH washes, and elution of DNA in 15 ml buffer EB (QIAGEN, 19086) . Each sample was quantified by Qubit, and measured for fragment lengths on a Tape Station. The samples were pooled and sequenced on an Illumina Nextseq 500 using 75 bp PE reads to a sequencing depth of 30 million reads per sample.
Whole exome sequencing
Whole exome sequencing (WES) of DNA from tumor and matched normal blood samples was done as previously described (Sade-Feldman et al., 2017) . Briefly, 250-500ng of extracted DNA, using QIAGEN AllPrep DNA/RNA Mini Kit (cat# 80204), was used as input for library preparation. Sample were barcoded using unique 8 base molecular barcodes followed by a library enrichment process, and all libraries above 40ng/ml were considered acceptable for solution-phase hybrid selection and sequencing. Libraries preparation was carried out using the SureSelect Target Enrichment System Sequencing Platform Library Prep v2 (Agilent Technologies, G3360-90000), according to manufacturer's specifications, followed by quantification and normalization using PicoGreen to ensure equal concentration. Libraries were then quantified using qPCR (KAPA Biosystems, KK4832), denturated with 0.2M NaOH and diluted to 20pM using hybridization buffer (Illumina 
QUANTIFICATION AND STATISTICAL ANALYSIS
Single cell RNA-seq data generation and processing FASTQ files were aligned to the NCBI Human Reference Genome Build GRCh37 (hg19) using STAR (Dobin et al., 2013) . Expression levels were quantified as Transcripts Per Million (TPM) and were computed by the RSEM tool (Li and Dewey, 2011) . For each cell, we used three quality control (QC) measures. We excluded: (1) cells with a zero expression of both CD45 and CD3E;
(2) cells expressing less than 1000 genes; (3) cells with an average expression of housekeeping genes (Table S6) , log 2 (TPM+1) < 2.5. For downstream analysis, we focused on protein coding genes (Table S6) , out of which, we used the set of genes with expression levels log 2 (TPM+1) > 4.5 in at least 10 cells per sample or genes with a particularly high expression level (log 2 (TPM+1) > 12) in one or more cells, per sample.
Supervised classification of single cells to cell types
To classify each single cell that passed QC to a pre-defined cell type, we performed a supervised analysis based on a list of known marker genes (Table S1 ). This was done by defining a set of genes per cell type which must or must not be expressed. On average, this approach led to the unambiguous classification of 80% of the cells. The remaining cells were then annotated using a manual review process. Following this step, we validated that no cell had an ambiguous classification (e.g., a T cell and a B cells).
Dimensionality reduction
The t-Distributed Stochastic Neighbor Embedding (t-SNE) method (Maaten and Hinton, 2008) was used for dimensionality reduction with the default perplexity parameter of 30 and initial dimension parameter of 10. Of note, t-SNE was used only for visualization and not for clustering, as defined below.
Unsupervised clustering of immune cells
To cluster all cells that passed QC we applied the k-means algorithm with a correlation distance metric, testing k = 3.15. The algorithm was applied using all genes with variance > 6, yielding $4000 genes. This value was selected based on the relation between the variance and the fraction of cells expressing each gene ( Figure S8A ). To determine the optimal number of clusters we applied the following steps: (1) We first examined how much of the complexity each cluster captures by applying the elbow method. This was done by computing the Pearson correlation matrix R and the distance matrix D as ð1 À RÞ. We then computed the sum of pairwise distances between all cells in different clusters Dis b = P k l = 1 P i˛Cl ;j;Cl Dði; jÞ ! and the total distance Dis t = P i;j Dði; jÞ. The ratio between these two measures V = Dis b =Dis t was used to estimate the variance explained by a given solution ( Figure S8B ), such that in the extreme case where all cells are clustered together or the case where each cell is a single cluster, this ratio would be 0 and 1, respectively. Exploring this ratio, we then select the solutions that are near plateau ðk = 10;.;15Þ.
(2) We then performed differential expression analysis (see below) to search for gene markers that are significantly more highly expressed in a specific cluster as compared to all other clusters. Then, in order avoid complex solutions, we excluded solutions with clusters that have too few marker genes (< 20) distinguishing between them and the rest of the cells.
(3) Finally, we performed a robustness analysis and selected the clustering solution with the highest median robustness score. Specifically, to determine the robustness of each clustering solution, we performed 100 iterations in which we randomly removed 10% of the cells, and re-ran the k-means algorithm and checked the stability of the clustering solution. We quantified the agreement of a given solution with the original one as the number of pairs of cells that were either clustered together, or not clustered together, in both solutions, divided by the total number pairs shared between the runs. This process yielded a median robustness measure of 0.96 for the selected k = 11 ( Figure S8C ). To examine if there is a significant difference between responders and non-responder lesions for a given cluster i, we computed the fraction of cells in each lesion assigned to cluster i, and applied the Wilcoxon rank-sum test to the corresponding values of responder and non-responder lesions. P values were corrected using the Benjamini-Hochberg False Discovery Rate (FDR) procedure and were considered significant if the FDR q-value was 0.1.
Unsupervised clustering of CD8 T cells
To identify different CD8 + T cell clusters we first extracted all single-cells classified as CD8 + in our supervised analysis. Our clustering process for CD8 + T cells followed the exact steps described above, testing possible clustering solutions for k = 2; .; 13 ( Figure S8D ). We then further explored the solutions with the highest variance explained ðk = 6;.;13Þ, and identified k = 6 as the optimal number of clusters, with a median robustness value of 0.93 ( Figure S8E ). In addition, we note for k = 2; .; 6 solutions had a hierarchical pattern in which whenever we increased k, a single cluster was split into two sub-clusters ( Figures S8F and S8G) . Similar to the analysis of all cells, to examine if there is a significant difference between responder and non-responder lesions for a given cluster i, we computed the fraction of CD8 + cells in each lesion assigned to cluster i, and applied the Wilcoxon rank-sum test to the corresponding values of responders and non-responder lesions. P values were corrected using the Benjamini-Hochberg False Discovery Rate (FDR) procedure and were considered significant if the FDR q-value was % 0.1.
Differential expression analysis
In all cases, differential expression analysis was applied to all genes that had an average expression level log 2 (TPM+1) > 2 in either tested groups, G 1 and G 2 . Then, for each gene i, we count the number of cells in G 1 and G 2 that express it with an expression level log 2 (TPM+1) > 2 or % 2. We then apply Fisher's Exact test for the corresponding 2x2 table. To identify significant differences we considered genes with a Bonferroni-corrected q-value % 0.05 and log 2 (fold-change) > 0.5.
Trajectory analysis of CD8 + T cells
To analyze the trajectory of CD8 + T cells based on single-cell RNA-seq expression data, we used Monocle v. 2.5.4 (Qiu et al., 2017) . As input to Monocle's Reversed Graph Embedding algorithm, we selected a set of 426 genes that was the union of the top 100 differentially expressed genes ordered by ascending q-value (as described above) for each of the six CD8 + T cell clusters (or all such genes for two clusters that had fewer than 100 significant genes). and used log 2 (TPM+1) values for quantification of expression levels. To compute the bad and good signature scores we computed the average expression of each set of marker genes (CD8_G = 34 genes, CD8_B = 1114 genes, Table S2 ).
DATA AND SOFTWARE AVAILABILITY
Data availability
Raw sequencing data (single cell RNaseq, WES and ATACseq) from this study have been deposited in dbGAP database (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001680.v1.p1) under accession number dbGAP: phs001680.v1.p1. Processed Single cell RNaseq data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus and are accessible through accession number GEO: GSE120575 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi? acc=GSE120575). The Van Allen (Van Allen et al., 2015) bulk RNA dataset used in this study is available in dbGAP database under accession number dbGAP: phs000452.v2.p1. Data from Riaz and Tirosh (Tirosh et al., 2016 ) studies used in this paper are available in under accession numbers GEO: GSE91061 and GEO: GSE72056 for the Riaz and Tirosh datasets, respectively. ATAC-seq data from the Schietinger group , used for the identification of unique peaks in PD-1 high and central memory (CM) cells is available with the accession number GEO: GSE89308. Figure S1 . Comparing the Composition of Known Cell Types to Clinical Outcomes and Checkpoint Therapy, Related to Figure 1 (A) tSNE plot of all CD45 + cells collected in this study. Cells are colored by cell type on the basis of pre-defined markers (Table S1 ). Pie chart summarizes the corresponding percentage of known cell types across all CD45 + cells collected in this cohort. (B) A comparison between the supervised classification of single cells to cell types (right color code) to the unsupervised clustering of immune cells identified by k-means clustering (left color code). For each one of the 11 unsupervised clusters identified, the percentage of cell types as defined by the supervised analysis is shown. Figure 4 (A) tSNE plot colored such that single-cells with a high expression level (log 2 (TPM+1)>2) of ENTPD1, HAVCR2, PDCD1, LAG3, TIGIT, TCF7, TNF, and IL7R are colored in red, and those with a low expression level (log 2 (TPM+1)<2) are colored in gray. Bar plots (to the right) summarize the corresponding percentages of each gene in the 6 identified clusters. (legend continued on next page)
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